**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 62228

**Manuscript Type:** MINIREVIEWS

**Transplantation of CD34+ cells for myocardial ischemia**

Matta A *et al*. CD34+ for myocardial ischemia

Anthony Matta, Vanessa Nader, Michel Galinier, Jerome Roncalli

**Anthony Matta, Vanessa Nader, Michel Galinier, Jerome Roncalli,** Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, Toulouse 31059, France

**Anthony Matta,** Faculty of Medicine, Holy Spirit University of Kaslik, Kaslik 00000, Lebanon

**Vanessa Nader,** Faculty of Pharmacy, Lebanese University, Beirut 961, Lebanon

**Author contributions:** Matta A contributed to conception, design and writing of the report; Nader V contributed to conception and design of the report; Galinier M revised the paper; Roncalli J contributed to design and writing of the report and provided important intellectual contributions to the study.

**Corresponding author: Jerome Roncalli, MD, PhD, Full Professor,** Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 1 Avenue Jean Poulhès, Toulouse 31059, France. roncalli.j@chu-toulouse.fr

**Received:** January 29, 2021

**Revised:** March 1, 2021

**Accepted:** April 13, 2021

**Published online:** May 18, 2021

**Abstract**

CD34+ cells are multipotent hematopoietic stem cells also known as endothelial progenitor cells and are useful in regenerative medicine. Naturally, these cells are mobilized from the bone marrow into peripheral circulation in response to ischemic tissue injury. CD34+ cells are known for their high proliferative and differentiation capacities that play a crucial role in the repair process of myocardial damage. They have an important paracrine activity in secreting factors to stimulate vasculogenesis, reduce endothelial cells and cardiomyocytes apoptosis, remodel extracellular matrix and activate additional progenitor cells. Once they migrate to the target site, they enhance angiogenesis, neovascularization and tissue regeneration. Several trials have demonstrated the safety and efficacy of CD34+ cell therapy in different settings, such as peripheral limb ischemia, stroke and cardiovascular disease. Herein, we review the potential utility of CD34+ cell transplantation in acute myocardial infarction, refractory angina and ischemic heart failure.

**Key Words:** Cell therapy; Endothelial progenitor cells; Myocardial ischemia; Refractory angina; Heart failure; Coronary microvascular dysfunction

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Matta A, Nader V, Galinier M, Roncalli J. Transplantation of CD34+ cells for myocardial ischemia. *World J Transplant* 2021; 11(5): 138-146

**URL:** https://www.wjgnet.com/2220-3230/full/v11/i5/138.htm

**DOI:** https://dx.doi.org/10.5500/wjt.v11.i5.138

**Core Tip:** CD34+ cells are mobilized from the bone marrow into the peripheral circulation in response to ischemic tissue injury. Once they migrate to the target site, they enhance angiogenesis, neovascularization and tissue regeneration. Safety and efficacy of CD34+ cell transplantation has been investigated in order to limit left ventricular dysfunction after acute myocardial infarction, refractory angina and heart failure.

**INTRODUCTION**

Ischemic heart disease or myocardial ischemia (MI) is a common disorder characterized by an imbalance between myocardial oxygen demand and supply. A wide spectrum of clinical manifestations ranging from chest discomfort to myocardial infarction is attributed to ischemic heart disease[1]. Conceptually, it is related to atherosclerotic coronary artery disease and considered the principal cause of death worldwide[2]. An epicardial coronary stenosis limits blood flow to a specific myocardial area, leading to ischemia, infarction and apoptosis[3]. In line with scientific development, microvascular dysfunction becomes responsible for a major part of MI[4]. It plays a crucial role by impairing the reactivity of coronary microcirculation in response to an increase in myocardial oxygen demand, which is equivalent to the effect of an obstructive plaque[4]. A large variety of therapeutic modalities targeting the pathophysiological patterns, consequences and underlying causes of MI are available.

CD34+ cell implantation has emerged as a promising approach to overcome the main limitations of conventional therapies by combining optimal medical treatment and myocardial revascularization by percutaneous coronary intervention or coronary artery bypass graft. CD34+ cells are multipotent hematopoietic stem cells also known as endothelial progenitor cells and are useful in regenerative medicine for treating ischemic injuries[5]. These cells are easily mobilized from the bone marrow into peripheral circulation and characterized by their ability to promote neoangiogenesis and cardiomyocyte regeneration[6]. Previous published trials have reported the effectiveness of CD34+ cell implantation for treating ischemic vascular disease like ischemic stroke, peripheral limb ischemia and MI[7,8]. Herein, we focus on the utility of CD34+ cell administration in the settings of myocardial infarction, refractory angina and ischemic heart failure.

**MECHANISMS OF ACTION OF CD34+ CELLS**

CD34+ cells are released into peripheral blood circulation in response to ischemic tissue injury. High circulating levels of CD34+ cells were detected after myocardial infarction[9]. These cells are known for their high proliferative and differentiation capacities that play a crucial role in the repair process after myocardial damage (Figure 1)[5]. Integrin antibodies, cysteine-rich angiogenic protein 61, stromal cell derived-factor 1 (SDF-1) and granulocyte colony stimulating factor were identified as agents incorporated in CD34+ cell mobilization from the bone marrow to peripheral circulation[10,11]. Then, an interaction between several factors (SDF-1, hepatocyte growth factor, vascular cell adhesion molecule, stem cell factor) and homing receptors such as CXC-chemokine receptor-4 is responsible for CD34+ cells traveling to ischemic tissue[12]. Once CD34+ cells migrate to the target site, they enhance angiogenesis, neovascularization and cardiac regeneration in two ways. First, CD34+ cells differentiate into smooth muscle cells and endothelial cells, which are the main structural components of internal vascular walls that lead to vascular re-endothelialization[13]. Second, they have an important paracrine role in secreting factors to stimulate vasculogenesis, reduce endothelial cell and cardiomyocyte apoptosis, remodel extracellular matrix and activate additional progenitor cells[5,13]. CD34+ cells produce angiogenic cytokines, such as interleukin-8, vascular epithelial growth factor and cytokine like 1[14]. A major part of their proangiogenic mechanism is mediated by producing exosomes (membrane-bound nanovesicles)[15]. These exosomes transfer proangiogenic microRNAs that may amplify the stem cell function and explain the angiogenic and therapeutic benefits associated with CD34+ stem cell therapy[15].

Limited data from the literature describe a beneficial effect of autologous CD34+ cell therapy on endothelial dependent/independent microvascular dysfunction[16]. Previous trials have reported a significant improvement in coronary flow reserve[17,18]. Lastly, replicative efficiency of endothelial progenitor cells is inversely correlated with age[19]. A decline in CD34+ cell function and in circulating number were associated with aging above 60 years[20,21] and type 2 diabetes mellitus[22,23].

**EFFICACY OF CD34+ CELL IMPLANTATION IN ISCHEMIC CARDIOVASCULAR DISEASE**

***Myocardial infarction***

Numerous trials have investigated the efficacy and safety of CD34+ cell therapy in the setting of acute myocardial infarction (AMI) (Table 1). In general, stimulation of angiogenesis and reduction in the infarct size, scar formation and myocardial fibrosis were commonly observed after CD34+ cell injection in the hibernating zone surrounding the infracted myocardial area[24-34]. Inhibition of cardiomyocyte apoptosis and collagen deposition were reported by Kocher *et al*[24] in an animal model. An improvement in left ventricular function was associated with CD34+ cell transplantation after AMI in human and nonhuman trials[25,28,29,32]. Shintani *et al*[30] observed a synergistic effect while combining CD34+ cells and vascular epithelial growth factor 2 gene therapies in the management of AMI, which yielded better outcomes. Also, Mackie *et al*[33] showed that injection of genetically modified CD34+ cells expressing sonic hedgehog protein enhanced angiogenic potency of CD34+ cells in ischemic myocardial tissue. In parallel, the injection of CD34+ cells deficient in microRNA377 following AMI significantly promoted angiogenesis and reduced left ventricle remodeling and cardiac fibrosis when compared to regular cells[34]. It is known that ischemic pre-conditioning (IPC) is beneficial for MI. Subsequently, Kamota *et al*[35] have demonstrated that this positive outcome was linked to the released cardioprotective factors in the early phase of IPC and to the CD34+ cells mobilization in the late phase of IPC.

Findings from the BONAMI trial showed that a decreased number of CD34+ cells in smokers was negatively correlated to viability recovery measured by single-photon emission computerized tomography at 3 mo post-AMI[36,37]. This suggests that these cells play a significant role after AMI. Thus, the PreSERVE-AMI trial revealed the safety of intracoronary injection of autologous CD34+ cells in revascularized ST-segment elevated myocardial infarction patients with altered left ventricular ejection fraction[38]. Indeed, a reduction in post-AMI major adverse cardiovascular events and an improvement in left ventricular function at 6 mo after cell injection were observed[39]. We noticed that therapeutic results of CD34+ cell implantation were dose-dependent[6,38-41]. Greater improvement was associated with higher doses with a threshold dose of over 10 million cells, particularly in the setting of myocardial infarction[40,41].

Subsequently, it was relevant to develop new delivery systems to allow the administration of higher numbers of CD34+ cells. The main purpose of the EXCELLENT trial (ClinicalTrials.gov Identifier: NCT02669810) was to evaluate the safety, tolerance and efficacy of intramyocardial injections of ProtheraCytes (autologous peripheral blood-CD34+ stem cells after automated *ex vivo* expansion with the StemXpandâ machine) in patients with AMI and decreased ejection fraction. In this ongoing trial, ProtheraCytes are currently reinjected using the BioCardia Helix biotherapeutic delivery system introduced through the femoral artery and guided towards the infarcted myocardium, thus avoiding surgical access.

***Refractory angina***

Intramyocardial injection of autologous CD34+ cells for the treatment of patients with refractory angina (Table 1) despite optimal medical therapy and no alternative therapeutic options has been studied considerably. Losordo *et al*[42] first showed the safety and favorable effectiveness of CD34+ cell therapy in these patients. The major positive effects included decreased frequency of weekly angina episodes and nitroglycerine use and improved Canadian Cardiovascular Society classification, exercise tolerance and quality of life[43,44]. Data from the ACT34-CMI study showed sustained efficacy of a single intramyocardial CD34+ cell injection for up to 2 years, with a significant reduction in deaths and major adverse cardiovascular events compared to those treated by placebo[45].

The incomplete RENEW phase III trial, which enrolled 112 of the 444 planned patients, failed to show a significant difference in total exercise time between the three study groups (CD34+ cells, placebo and conventional therapy) at 3, 6 and 12 mo[46]. However, it did confirm the findings from previous studies concerning the safety and efficacy of intramyocardial CD34+ cell therapy on angina frequency[47]. The efficacy and safety of intracoronary administration of CD34+ cells for refractory angina were evaluated in patients unsuitable for revascularization strategies with diffuse obstructive coronary artery disease[47,48]. A reduction in weekly angina frequency without significant adverse events were observed. A recently published study by Johnson *et al*[49] showed a significant reduction in mortality, cardiac-related admissions, hospital visits, coronary interventions and health care costs in the 12 mo following intramyocardial administration of CD34+ cells compared to the year before their injection.

***Heart failure***

CD34+ cell therapy was investigated in ischemic and non-ischemic dilated cardiomyopathy (DCM) (Table 1). Improvement in the 6-min walk test, left ventricular ejection fraction, N-terminal pro brain natriuretic peptide level and resting myocardial perfusion were observed after intracoronary injection of autologous CD34+ cells in patients with non-ischemic DCM and reduced ejection fraction[50-52]. Similar results with improvement in diastolic function were found by Bervar *et al*[53] after transendocardial CD34+ cell delivery in non-ischemic heart failure patients. Also, a significant decrease in the prevalence of heart failure and total mortality rate without a difference in the prevalence of sudden cardiac death were observed at 5 years after CD34+ cell transplantation therapy[50].

In patients with ischemic cardiomyopathy and left ventricular ejection fraction below 40%, Poglajen *et al*[54] observed significant amelioration in left ventricular ejection fraction, 6-min walk test and N-terminal pro brain natriuretic peptide levels after transendocardial injection of CD34+ cells into hibernating myocardium, while no change in these parameters was observed after optimal medical treatment. It is noteworthy that greater clinical improvement was associated with higher delivered doses and extended injections[54]. Comparing delivery routes of CD34+ cells in DCM patients, a significantly better response was correlated with transendocardial administration than with intracoronary injections[55]. However, CD34+ cell transplantation was not beneficial in diabetic patients with non-ischemic DCM as shown by a small study sample size[56].

***Coronary microvascular dysfunction***

Currently, coronary microvascular dysfunction (CMD) is a hot topic in cardiology. It plays a pivotal role in the pathophysiology of myocardial infarction with nonobstructive coronary artery disease, which accounts for 10% of acute coronary syndromes[57]. While therapeutic options are limited, the role of CD34+ cell therapy remains unclear in CMD, and available data are scarce in the literature (Table 1)[16]. Otherwise, reduced circulating levels of CD34+ cells were detected in the presence of coronary endothelial dysfunction even in the absence of atherosclerotic disease[58,59]. REPAIR-AMI and TOPCARE-AMI trials reported potential benefits of intracoronary injection of autologous CD34+ cells on CMD by revealing a normalization of coronary flow reserve in the studied AMI population[17,18]. Additionally, two ongoing trials are investigating the safety and efficacy of CD34+ cell therapy in patients with CMD (CLBS14 trial, ClinicalTrials.gov Identifier: NCT03508609; CD34 trial, ClinicalTrials.gov Identifier: NCT03471611).

**CONCLUSION**

Regenerative medicine is a promising therapeutic approach for acquired cardiovascular disease, and routine use of stem cell therapy would be an ultimate goal of this area. Several clinical trials support the safety and efficacy of autologous CD34+ cell transplantation in AMI, refractory angina and systolic heart failure. Administration of genetically modified CD34+ sonic hedgehog+ microRNA377- cells amplifies the angiogenic target. Intramyocardial injection is likely the preferred delivery route, and a threshold dose over 10 million cells is desirable at least in the setting of AMI. Future studies investigating the tolerability and efficacy of allogenic CD34+ cells from youthful donors into elderly and diabetic recipients are warranted. Moving beyond clinical trials and translation of preliminary data into clinical practice after establishing a standardized procedure for CD34+ cell transplantation may revolutionize the management and overall prognosis of ischemic cardiovascular disease.

**REFERENCES**

1 **Irwin S**. Clinical manifestations and assessment of ischemic heart disease. *Phys Ther* 1985; **65**: 1806-1811 [PMID: 3906685 DOI: 10.1093/ptj/65.12.1806]

2 **Nowbar AN**, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality From Ischemic Heart Disease. *Circ Cardiovasc Qual Outcomes* 2019; **12**: e005375 [PMID: 31163980 DOI: 10.1161/CIRCOUTCOMES.118.005375]

3 **Rezende PC**, Ribas FF, Serrano CV Jr, Hueb W. Clinical significance of chronic myocardial ischemia in coronary artery disease patients. *J Thorac Dis* 2019; **11**: 1005-1015 [PMID: 31019790 DOI: 10.21037/jtd.2019.02.85]

4 **Kaski JC**, Crea F, Gersh BJ, Camici PG. Reappraisal of Ischemic Heart Disease. *Circulation* 2018; **138**: 1463-1480 [PMID: 30354347 DOI: 10.1161/CIRCULATIONAHA.118.031373]

5 **Roncalli JG**, Tongers J, Renault MA, Losordo DW. Endothelial progenitor cells in regenerative medicine and cancer: a decade of research. *Trends Biotechnol* 2008; **26**: 276-283 [PMID: 18359114 DOI: 10.1016/j.tibtech.2008.01.005]

6 **Hénon P**. Key Success Factors for Regenerative Medicine in Acquired Heart Diseases. *Stem Cell Rev Rep* 2020; **16**: 441-458 [PMID: 32297205 DOI: 10.1007/s12015-020-09961-0]

7 **Sietsema WK**, Kawamoto A, Takagi H, Losordo DW. Autologous CD34+ Cell Therapy for Ischemic Tissue Repair. *Circ J* 2019; **83**: 1422-1430 [PMID: 31178469 DOI: 10.1253/circj.CJ-19-0240]

8 **Roncalli J**, Tongers J, Renault MA, Losordo DW. Biological approaches to ischemic tissue repair: gene- and cell-based strategies. *Expert Rev Cardiovasc Ther* 2008; **6**: 653-668 [PMID: 18510483 DOI: 10.1586/14779072.6.5.653]

9 **Wojakowski W**, Tendera M, Michałowska A, Majka M, Kucia M, Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. *Circulation* 2004; **110**: 3213-3220 [PMID: 15533859 DOI: 10.1161/01.CIR.0000147609.39780.02]

10 **Qin G**, Ii M, Silver M, Wecker A, Bord E, Ma H, Gavin M, Goukassian DA, Yoon YS, Papayannopoulou T, Asahara T, Kearney M, Thorne T, Curry C, Eaton L, Heyd L, Dinesh D, Kishore R, Zhu Y, Losordo DW. Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. *J Exp Med* 2006; **203**: 153-163 [PMID: 16401693 DOI: 10.1084/jem.20050459]

11 **Grote K**, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B. The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. *Blood* 2007; **110**: 877-885 [PMID: 17429007 DOI: 10.1182/blood-2006-07-036202]

12 **Theiss HD**, David R, Engelmann MG, Barth A, Schotten K, Naebauer M, Reichart B, Steinbeck G, Franz WM. Circulation of CD34+ progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and ICM). *Eur Heart J* 2007; **28**: 1258-1264 [PMID: 17395679 DOI: 10.1093/eurheartj/ehm011]

13 **Tongers J**, Roncalli JG, Losordo DW. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. *Microvasc Res* 2010; **79**: 200-206 [PMID: 20144623 DOI: 10.1016/j.mvr.2010.01.012]

14 **Schneller D**, Hofer-Warbinek R, Sturtzel C, Lipnik K, Gencelli B, Seltenhammer M, Wen M, Testori J, Bilban M, Borowski A, Windwarder M, Kapel SS, Besemfelder E, Cejka P, Habertheuer A, Schlechta B, Majdic O, Altmann F, Kocher A, Augustin HG, Luttmann W, Hofer E. Cytokine-Like 1 Is a Novel Proangiogenic Factor Secreted by and Mediating Functions of Endothelial Progenitor Cells. *Circ Res* 2019; **124**: 243-255 [PMID: 30582450 DOI: 10.1161/CIRCRESAHA.118.313645]

15 **Mathiyalagan P**, Liang Y, Kim D, Misener S, Thorne T, Kamide CE, Klyachko E, Losordo DW, Hajjar RJ, Sahoo S. Angiogenic Mechanisms of Human CD34+ Stem Cell Exosomes in the Repair of Ischemic Hindlimb. *Circ Res* 2017; **120**: 1466-1476 [PMID: 28298297 DOI: 10.1161/CIRCRESAHA.116.310557]

16 **Prasad M**, Corban MT, Henry TD, Dietz AB, Lerman LO, Lerman A. Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. *Cardiovasc Res* 2020; **116**: 1424-1433 [PMID: 32022845 DOI: 10.1093/cvr/cvaa027]

17 **Erbs S**, Linke A, Schächinger V, Assmus B, Thiele H, Diederich KW, Hoffmann C, Dimmeler S, Tonn T, Hambrecht R, Zeiher AM, Schuler G. Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial. *Circulation* 2007; **116**: 366-374 [PMID: 17620510 DOI: 10.1161/CIRCULATIONAHA.106.671545]

18 **Schächinger V**, Assmus B, Honold J, Lehmann R, Hofmann WK, Martin H, Dimmeler S, Zeiher AM. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. *Clin Res Cardiol* 2006; **95**: 13-22 [PMID: 16598441 DOI: 10.1007/s00392-006-0314-x]

19 **Al Mheid I**, Hayek SS, Ko YA, Akbik F, Li Q, Ghasemzadeh N, Martin GS, Long Q, Hammadah M, Maziar Zafari A, Vaccarino V, Waller EK, Quyyumi AA. Age and Human Regenerative Capacity Impact of Cardiovascular Risk Factors. *Circ Res* 2016; **119**: 801-809 [PMID: 27436845 DOI: 10.1161/CIRCRESAHA.116.308461]

20 **Mozid AM**, Jones D, Arnous S, Saunders N, Wragg A, Martin J, Agrawal S, Mathur A. The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease. *Stem Cells Dev* 2013; **22**: 216-223 [PMID: 22834565 DOI: 10.1089/scd.2012.0139]

21 **Wu TW**, Liu CC, Hung CL, Yen CH, Wu YJ, Wang LY, Yeh HI. Genetic profiling of young and aged endothelial progenitor cells in hypoxia. *PLoS One* 2018; **13**: e0196572 [PMID: 29708992 DOI: 10.1371/journal.pone.0196572]

22 **Mavromatis K**, Ghasemzadeh N, Forghani Z, Hameed S, Waller EK, Quyyumi AA, Taylor W. Patients with diabetes have reduced circulating CD34+ cells after coronary stenting. *Arterioscler Thromb Vasc Biol* 2008; **28**: E77

23 **Yamashita A**, Nishihira K, Matsuura Y, Ito T, Kawahara K, Hatakeyama K, Hashiguchi T, Maruyama I, Yagi H, Matsumoto M, Fujimura Y, Kitamura K, Shibata Y, Asada Y. Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. *Atherosclerosis* 2012; **224**: 511-514 [PMID: 22862965 DOI: 10.1016/j.atherosclerosis.2012.07.027]

24 **Kocher AA**, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001; **7**: 430-436 [PMID: 11283669 DOI: 10.1038/86498]

25 **Kawamoto A**, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Zak V, Asahara T, Losordo DW. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. *Circulation* 2006; **114**: 2163-2169 [PMID: 17075009 DOI: 10.1161/CIRCULATIONAHA.106.644518]

26 **Botta R**, Gao E, Stassi G, Bonci D, Pelosi E, Zwas D, Patti M, Colonna L, Baiocchi M, Coppola S, Ma X, Condorelli G, Peschle C. Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells. *FASEB J* 2004; **18**: 1392-1394 [PMID: 15231728 DOI: 10.1096/fj.03-0879fje]

27 **Brenner W**, Aicher A, Eckey T, Massoudi S, Zuhayra M, Koehl U, Heeschen C, Kampen WU, Zeiher AM, Dimmeler S, Henze E. 111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. *J Nucl Med* 2004; **45**: 512-518 [PMID: 15001696]

28 **Ott I**, Keller U, Knoedler M, Götze KS, Doss K, Fischer P, Urlbauer K, Debus G, von Bubnoff N, Rudelius M, Schömig A, Peschel C, Oostendorp RA. Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction. *FASEB J* 2005; **19**: 992-994 [PMID: 15814609 DOI: 10.1096/fj.04-3219fje]

29 **Yoshioka T**, Ageyama N, Shibata H, Yasu T, Misawa Y, Takeuchi K, Matsui K, Yamamoto K, Terao K, Shimada K, Ikeda U, Ozawa K, Hanazono Y. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. *Stem Cells* 2005; **23**: 355-364 [PMID: 15749930 DOI: 10.1634/stemcells.2004-0200]

30 **Shintani S**, Kusano K, Ii M, Iwakura A, Heyd L, Curry C, Wecker A, Gavin M, Ma H, Kearney M, Silver M, Thorne T, Murohara T, Losordo DW. Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. *Nat Clin Pract Cardiovasc Med* 2006; **3 Suppl 1**: S123-S128 [PMID: 16501618 DOI: 10.1038/ncpcardio0430]

31 **Zhang S**, Ge J, Zhao L, Qian J, Huang Z, Shen L, Sun A, Wang K, Zou Y. Host vascular niche contributes to myocardial repair induced by intracoronary transplantation of bone marrow CD34+ progenitor cells in infarcted swine heart. *Stem Cells* 2007; **25**: 1195-1203 [PMID: 17272498 DOI: 10.1634/stemcells.2006-0605]

32 **Wang J**, Zhang S, Rabinovich B, Bidaut L, Soghomonyan S, Alauddin MM, Bankson JA, Shpall E, Willerson JT, Gelovani JG, Yeh ET. Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. *Circ Res* 2010; **106**: 1904-1911 [PMID: 20448213 DOI: 10.1161/CIRCRESAHA.110.221762]

33 **Mackie AR**, Klyachko E, Thorne T, Schultz KM, Millay M, Ito A, Kamide CE, Liu T, Gupta R, Sahoo S, Misener S, Kishore R, Losordo DW. Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction. *Circ Res* 2012; **111**: 312-321 [PMID: 22581926 DOI: 10.1161/CIRCRESAHA.112.266015]

34 **Joladarashi D**, Garikipati VNS, Thandavarayan RA, Verma SK, Mackie AR, Khan M, Gumpert AM, Bhimaraj A, Youker KA, Uribe C, Suresh Babu S, Jeyabal P, Kishore R, Krishnamurthy P. Enhanced Cardiac Regenerative Ability of Stem Cells After Ischemia-Reperfusion Injury: Role of Human CD34+ Cells Deficient in MicroRNA-377. *J Am Coll Cardiol* 2015; **66**: 2214-2226 [PMID: 26564600 DOI: 10.1016/j.jacc.2015.09.009]

35 **Kamota T**, Li TS, Morikage N, Murakami M, Ohshima M, Kubo M, Kobayashi T, Mikamo A, Ikeda Y, Matsuzaki M, Hamano K. Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. *J Am Coll Cardiol* 2009; **53**: 1814-1822 [PMID: 19422991 DOI: 10.1016/j.jacc.2009.02.015]

36 **Roncalli J**, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. *Eur Heart J* 2011; **32**: 1748-1757 [PMID: 21127322 DOI: 10.1093/eurheartj/ehq455]

37 **Lamirault G**, de Bock E, Sébille V, Delasalle B, Roncalli J, Susen S, Piot C, Trochu JN, Teiger E, Neuder Y, Le Tourneau T, Manrique A, Hardouin JB, Lemarchand P. Sustained quality of life improvement after intracoronary injection of autologous bone marrow cells in the setting of acute myocardial infarction: results from the BONAMI trial. *Qual Life Res* 2017; **26**: 121-125 [PMID: 27439601 DOI: 10.1007/s11136-016-1366-7]

38 **Quyyumi AA**, Vasquez A, Kereiakes DJ, Klapholz M, Schaer GL, Abdel-Latif A, Frohwein S, Henry TD, Schatz RA, Dib N, Toma C, Davidson CJ, Barsness GW, Shavelle DM, Cohen M, Poole J, Moss T, Hyde P, Kanakaraj AM, Druker V, Chung A, Junge C, Preti RA, Smith RL, Mazzo DJ, Pecora A, Losordo DW. PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. *Circ Res* 2017; **120**: 324-331 [PMID: 27821724 DOI: 10.1161/CIRCRESAHA.115.308165]

39 **Iwasaki H**, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. *Circulation* 2006; **113**: 1311-1325 [PMID: 16534028 DOI: 10.1161/CIRCULATIONAHA.105.541268]

40 **Quyyumi AA**, Waller EK, Murrow J, Esteves F, Galt J, Oshinski J, Lerakis S, Sher S, Vaughan D, Perin E, Willerson J, Kereiakes D, Gersh BJ, Gregory D, Werner A, Moss T, Chan WS, Preti R, Pecora AL. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. *Am Heart J* 2011; **161**: 98-105 [PMID: 21167340 DOI: 10.1016/j.ahj.2010.09.025]

41 **Poole JC**, Quyyumi AA. Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells. *Stem Cells Int* 2013; **2013**: 658480 [PMID: 23737803 DOI: 10.1155/2013/658480]

42 **Losordo DW**, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. *Circulation* 2007; **115**: 3165-3172 [PMID: 17562958 DOI: 10.1161/CIRCULATIONAHA.106.687376]

43 **Losordo DW**, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA; ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. *Circ Res* 2011; **109**: 428-436 [PMID: 21737787 DOI: 10.1161/CIRCRESAHA.111.245993]

44 **Benck L**, Henry TD. CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval? *Cardiovasc Revasc Med* 2019; **20**: 177-178 [PMID: 30904135 DOI: 10.1016/j.carrev.2019.01.012]

45 **Henry TD**, Schaer GL, Traverse JH, Povsic TJ, Davidson C, Lee JS, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Patel AN, Riedel N, Junge C, Hunt A, Kereiakes DJ, White C, Harrington RA, Schatz RA, Losordo DW; ACT. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. *Cell Transplant* 2016; **25**: 1701-1711 [PMID: 27151378 DOI: 10.3727/096368916X691484]

46 **Povsic TJ**, Henry TD, Traverse JH, Fortuin FD, Schaer GL, Kereiakes DJ, Schatz RA, Zeiher AM, White CJ, Stewart DJ, Jolicoeur EM, Bass T, Henderson DA, Dignacco P, Gu Z, Al-Khalidi HR, Junge C, Nada A, Hunt AS, Losordo DW; RENEW Investigators. The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. *JACC Cardiovasc Interv* 2016; **9**: 1576-1585 [PMID: 27491607 DOI: 10.1016/j.jcin.2016.05.003]

47 **Wang S**, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angina. *Cardiology* 2010; **117**: 140-147 [PMID: 20975266 DOI: 10.1159/000320217]

48 **Lee FY**, Chen YL, Sung PH, Ma MC, Pei SN, Wu CJ, Yang CH, Fu M, Ko SF, Leu S, Yip HK. Intracoronary Transfusion of Circulation-Derived CD34+ Cells Improves Left Ventricular Function in Patients With End-Stage Diffuse Coronary Artery Disease Unsuitable for Coronary Intervention. *Crit Care Med* 2015; **43**: 2117-2132 [PMID: 26154930 DOI: 10.1097/CCM.0000000000001138]

49 **Johnson GL**, Henry TD, Povsic TJ, Losordo DW, Garberich RF, Stanberry LI, Strauss CE, Traverse JH. CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina. *Stem Cells Transl Med* 2020; **9**: 1147-1152 [PMID: 32531108 DOI: 10.1002/sctm.20-0046]

50 **Vrtovec B**, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. *Circ Res* 2013; **112**: 165-173 [PMID: 23065358 DOI: 10.1161/CIRCRESAHA.112.276519]

51 **Lezaic L**, Socan A, Poglajen G, Peitl PK, Sever M, Cukjati M, Cernelc P, Wu JC, Haddad F, Vrtovec B. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. *J Card Fail* 2015; **21**: 145-152 [PMID: 25459687 DOI: 10.1016/j.cardfail.2014.11.005]

52 **Vrtovec B**, Poglajen G, Sever M, Lezaic L, Domanovic D, Cernelc P, Haddad F, Torre-Amione G. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. *J Card Fail* 2011; **17**: 272-281 [PMID: 21440864 DOI: 10.1016/j.cardfail.2010.11.007]

53 **Bervar M**, Kozelj M, Poglajen G, Sever M, Zemljic G, Frljak S, Cukjati M, Cernelc P, Haddad F, Vrtovec B. Effects of Transendocardial CD34+ Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated Cardiomyopathy. *Stem Cells Transl Med* 2017; **6**: 1515-1521 [PMID: 28296283 DOI: 10.1002/sctm.16-0331]

54 **Poglajen G**, Sever M, Cukjati M, Cernelc P, Knezevic I, Zemljic G, Haddad F, Wu JC, Vrtovec B. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. *Circ Cardiovasc Interv* 2014; **7**: 552-559 [PMID: 25097199 DOI: 10.1161/CIRCINTERVENTIONS.114.001436]

55 **Vrtovec B**, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. *Circulation* 2013; **128**: S42-S49 [PMID: 24030420 DOI: 10.1161/CIRCULATIONAHA.112.000230]

56 **Vrtovec B**, Sever M, Jensterle M, Poglajen G, Janez A, Kravos N, Zemljic G, Cukjati M, Cernelc P, Haddad F, Wu JC, Jorde UP. Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance. *Stem Cells Transl Med* 2016; **5**: 632-638 [PMID: 27025690 DOI: 10.5966/sctm.2015-0172]

57 **Niccoli G**, Camici PG. Myocardial infarction with non-obstructive coronary arteries: what is the prognosis? *Eur Heart J Suppl* 2020; **22**: E40-E45 [PMID: 32523437 DOI: 10.1093/eurheartj/suaa057]

58 **Boilson BA**, Kiernan TJ, Harbuzariu A, Nelson RE, Lerman A, Simari RD. Circulating CD34+ cell subsets in patients with coronary endothelial dysfunction. *Nat Clin Pract Cardiovasc Med* 2008; **5**: 489-496 [PMID: 18578002 DOI: 10.1038/ncpcardio1277]

59 **Hale G**, Waldmann H. Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation. *Bone Marrow Transplant* 1997; **20**: 709-710 [PMID: 9383240 DOI: 10.1038/sj.bmt.1700956]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 29, 2021

**First decision:** February 25, 2021

**Article in press:** April 13, 2021

**Specialty type:** Transplantation

**Country/Territory of origin:** France

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Zhao L **S-Editor:** Gao CC **L-Editor:** A **P-Editor:** Yuan YY

**Figure Legends**



**Figure 1 Role of CD34+ cells in ischemic myocardial repair.** A: In response to ischemic injury, several factors like granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin (IL)-3, IL-8, IL-11, cysteine-rich angiogenic protein 61 (CCN1) and integrin antibodies (Antiα4β1) trigger mobilization of CD34+ cells from the bone marrow into peripheral circulation; B: Mechanisms of action of CD34+ cells on cardiomyocytes *via* paracrine activity are transdifferentiation into smooth muscle and endothelial cells, neovascularization, matrix remodeling, reduced apoptosis and recruitment of additional stem/progenitor cells; C: The main cardiovascular outcomes of CD34+ cells. G-CSF: Granulocyte colony stimulating factor; GM-CSF: Granulocyte macrophage colony stimulating factor; IL: Interleukin; CCN1: Cysteine-rich angiogenic protein 61.

**Table 1 Summary of clinical studies of CD34+ cell therapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Disease** | **Ref.** | **Model** | **Delivery route** | **Results** |
| Myocardial infarction | Kocher *et al*[24] | Animal | Intravenous | (+) Angiogenesis; (-) Cardiomyocyte apoptosis, collagen deposition, scar formation |
| Kawamoto *et al*[25] | Human | Intramyocardial | (+) Angiogenesis, cardiac function; (-) Myocardial fibrosis |
| Botta *et al*[26] | Animal | Intramyocardial | (+) Cardiac function; (+) Cardiac hemodynamics with CD34+ KDR+ subset |
| Brenner *et al*[27] | Animal | Intracavitary of LV | (+) LV function |
| Ott *et al*[28] | Animal | Intramyocardial | (+) LVEF |
| Yoshioka *et al*[29] | Human | Intracardiac | (+) Blood flow; (+) Cardiac function |
| Shintani *et al*[30] | Animal | Intramyocardial | (+) Capillary density; (-) Myocardial infarct size |
| Zhang *et al*[31] | Animal | Intracoronary | (+) Cardiac repair, therapeutic benefits |
| Wang *et al*[32] | Animal | Intramyocardial | (+) Angiogenesis, cardiac function |
| Mackie *et al*[33] | Animal | Intramyocardial | (+) Capillary density; (-) Ventricular dilation, infarct size, cardiac function alteration |
| Joladarashi *et al*[34] | Animal | Intramyocardial | (+) Angiogenesis; (-) LV remodeling and cardiac fibrosis with CD34 deficient microRNA 377 |
| Quyyumi *et al*[38] | Human | Intracoronary | (+) LVEF; (-) Infarct size and MACE |
| Quyyumi *et al*[40] | Human | Intracoronary | (+) Infarcted area perfusion |
| Refractory angina | Losordo *et al*[43] | Human | Intramyocardial | (+) Exercise tolerance; (-) Angina frequency, 12 mo mortality |
| Henry *et al*[45] | Human | Intramyocardial | (-) Angina frequency at 2 yr |
| Povsic *et al*[46] | Human | Intramyocardial | (-) Angina frequency |
| Wang *et al*[47] | Human | Intramyocardial | (+) Myocardial perfusion by PET; (-) Angina frequency |
| Lee *et al*[48] | Human | Intracoronary | (+) LVEF; (-) Angina frequency |
| Johnson *et al*[49] | Human | Intramyocardial | (-) Mortality, cardiac admissions, hospital visits, health care costs |
| Heart failure (dilated cardiomyopathy) | Vrtovec *et al*[50] | Human | Intracoronary | (+) LVEF, 6MWD; (-) NT-proBNP, mortality |
| Lezaic *et al*[51] | Human | Intracoronary | (+) Myocardial perfusion, LVEF, 6MWD |
| Bervar *et al*[53] | Human | Transendocardial | (+) 6MWD, diastolic function; (-) NT-proBNP |
| Poglajen *et al*[54] | Human | Transendocardial | (+) 6MWD, LVEF; (-) NT-proBNP |
| Coronary microvascular dysfunction | Erbs *et al*[17] | Human | Intracoronary | (+) CFR |
| Schächinger *et al*[18] | Human | Intracoronary | (+) CFR |

6MWD: 6-min walk distance; CFR: Coronary flow reserve; KDR: Vascular endothelial growth factor receptor 2; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MACE: Major adverse cardiovascular events; NT-proBNP: N-terminal pro brain natriuretic peptide; PET: Positron emission tomography.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**